• Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to show a fall in quarterly revenue when it reports results on May 13 for the period ending March 31 2026

• The Nashville Tennessee-based company is expected to report a 86.0% decrease in revenue to $300 thousand from $2.14 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Insight Molecular Diagnostics Inc is for a loss of 26 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $9.00, about 83.3% above its last closing price of $4.91

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated May 11 at 23:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)